cxcr7 antagonist 1

CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7. CXCR7 antagonist-1 prevents tumor cell proliferation and tumor formation and can be used in studies about inflammatory diseases.

CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits binding of SDF-1 chemokine (CXCL12 chemokine) or I-TAC to CXCR7, applicable for tumor and inflammation research.

Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.

Plerixafor-d4 is the deuterated form of Plerixafor. Plerixafor (AMD 3100) acts as a selective CXCR4 antagonist with an IC50 of 44 nM. It serves as an immunostimulant and a hematopoietic stem cell mobilizer, and it also functions as an allosteric agonist of CXCR7. Plerixafor inhibits the replication of HIV-1 and HIV-2 with an EC50 of 1-10 nM.

Balixafortide (POL6326) is a potent, selective, and well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM, and also acts as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. It demonstrates anti-cancer effects[1][2], blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM, and is 1000-fold more selective for CXCR4 than a large panel of receptors, including CXCR7.